CD274 and neoplasm: For example, for patients with metastatic triple-negative breast cancer receiving pembrolizumab, their tumors must have a combined positive score ([CPS] (the number of PD-L1–staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100) of at least 10 [42].